Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
Conditions: Neoplasms Interventions: Drug: Erlotinib; Drug: Lenvatinib; Drug: Axitinib Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Conditions: Non-small Cell Lung Cancer; EGFR Gene Mutation; EGFR-TKI Resistant Mutation Interventions: Drug: Nintedanib, gefitinib, erlotinib, afatinib Sponsors: China Medical University Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Conditions: Solid Tumors; Advanced Solid Tumors; Metastatic Cancer Interventions: Drug: bevacizumab; Drug: erlotinib Sponsors: Asan Medical Center; Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
Condition: Non-Small Cell Lung Cancer Interventions: Drug: lorlatinib; Drug: crizotinib; Drug: brigatinib; Drug: ceritinib; Drug: alectinib; Drug: atezolizumab; Drug: bevacizumab; Drug: paclitaxel; Drug: carboplatin; Drug: docetaxel; Drug: erlotinib; Drug: gefitinib; Drug: afatinib; Drug: dacomi tinib; Drug: osimertinib; Drug: pembrolizumab; Drug: nivolumab; Drug: entrectinib Sponsor: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 28, 2023 Category: Research Source Type: clinical trials
